A randomised trial to investigate the effect of Elafin on myocardial injury and inflammation in coronary artery bypass surgery.

Trial Profile

A randomised trial to investigate the effect of Elafin on myocardial injury and inflammation in coronary artery bypass surgery.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs Elafin (Primary)
  • Indications Myocardial reperfusion injury
  • Focus Proof of concept; Therapeutic Use
  • Acronyms EMPIRE
  • Most Recent Events

    • 26 Aug 2015 Results published in the Heart.
    • 26 Aug 2015 Primary endpoint (Area under the curve (AUC) for plasma troponin I concentration over 48 hours.) has not been met as per results published in the Heart.
    • 13 Mar 2015 Interim results (significant reduction in troponin I after 6 hours) published in Proteo, Inc Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top